TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Long Term, Follow-on Study of Lomitapide in Patients With Homozygous Familial Hypercholesterolemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Completed UP1002 or 733-005.~2. Willing and able to provide consent and comply with the requirements of the study protocol.~Exclusion Criteria:~1. Met any of the stopping rules for study discontinuation at the final visit of study UP1002 or 733-005.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- lomitapide (Type: EXPERIMENTAL): Maximum tolerated dose of lomitapide in addition to existing lipid lowering therapy including plasmapheresis or lipid apheresis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Argatroban in Ischemic Stroke With Early Deterioration (EASE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* AIS patients with typical symptoms and signs within 48h, including those who received intravenous thrombolysis for 24 hours.~* The neurologic function deteriorated from 6h to 48h after the onset of the disease, and the NIHSS score increased by ≥ 2 points;~* Sign informed consent.~Exclusion Criteria:~* The diagnosis was cardiogenic cerebral embolism;~* In the patients with large area cerebral infarction of anterior circulation, the focus area was larger than 2 / 3 of the area of cerebral hemisphere;~* Patients with NIHSS score ≥ 21;~* Patients with conversion of intracranial hemorrhage;~* Patients with tirofiban;~* Patients with blood pressure ≥ 180 / 110mmhg after treatment;~* There were severe heart, liver and kidney dysfunction, such as LVEF \< 40%, serum AST and ALT increased to 3 times of the upper limit of normal, creatinine clearance \< 30ml / min;~* Patients with hematological diseases and those with bleeding tendency;~* In the past 6 months, the patients had a history of severe gastrointestinal hemorrhage;~* Allergic to argatraban;~* Patients (such as those with mental and mental disorders) who are not suitable for the clinical study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- control (Type: NO_INTERVENTION): Standard medical treatment, including routine antiplatelet, blood pressure control, statins to stabilize plaque, etc.
- Argatroban group (Type: EXPERIMENTAL): Argatraban is used on the basis of standard medical treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of SPARC0912 and Reference0912 in Open Angle Glaucoma or Ocular Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women aged ≥ 18 years.~* Diagnosis of ocular hypertension (OHT) or primary open angle glaucoma (POAG).~* Unmedicated IOP ≥ 22 mmHg in one or both eyes.~* Given informed consent.~* Women of child bearing potential practicing an acceptable method of birth control with a negative urine pregnancy test.~Exclusion Criteria:~* Known lack of ocular hypotensive response to topical ophthalmic, prostaglandin analogs (in the opinion of the investigator).~* Intraocular conventional surgery or laser surgery within the past six months.~* Refractive surgery in study eye (e.g., radial keratotomy, PRK, LASIK, etc.) within the past 3 months.~* Angle closure glaucoma or a history of acute angle closure treated with a peripheral iridotomy.~* Ocular trauma within the past 3 months.~* Progressive retinal or optic nerve disease apart from glaucoma.~* Concurrent infectious/non infectious conjunctivitis, keratitis, or uveitis in either eye.~* Any abnormality preventing stable applanation tonometry.~* Use of contact lens for the duration of the study.~* Any opacity or subject uncooperativeness that restricts adequate examination of the ocular fundus or anterior chamber.~* Clinically significant ocular disease (e.g., corneal edema, uveitis, severe keratoconjunctivitis sicca) which might interfere with the study, including glaucomatous damage so severe that washout of ocular hypotensive medications is not judged safe.~* Clinically significant systemic disease which might interfere with the study.~* History of non-compliance to medical regimens or unwilling to comply with the study protocol.~* Participation in another clinical study within the last thirty (30) days.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SPARC0912 (Type: EXPERIMENTAL): Test drug
- Reference0912 (Type: EXPERIMENTAL): Reference drug

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dexamethasone and Wound Healing After Thyroid Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Elective total thyroidectomy or hemithyroidectomy with lymphadenectomy for thyroid cancer~Exclusion Criteria:~* Age \> 65 years, \< 18 years~* Thyroid tumor with Grave's disease~* Thyroid tumor size over 5 cm~* Second or more than 2 times for thyroid surgery~* Non-traditional pathway for thyroid surgery~* ASA \> II~* Pharyngitis~* Smoking, alcohol drinking history~* Contraindication or long term use of dexamethasone (allege, ulcer bleeding history, et al)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Group D (Type: ACTIVE_COMPARATOR): Group D: dexamethasone group
- Group S (Type: PLACEBO_COMPARATOR): Group S: saline group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 2 months old infants on the day of inclusion~* Born at full term of pregnancy (≥ 37 weeks) with a birth weight ≥ 2.5 kg~* Informed consent form signed by one or both parents or by the legally acceptable representative and 1 or 2 independent witnesses~* Able to attend all scheduled visits and to comply with all trial procedures~* Has complied with the national immunization calendar (BCG for both countries) for the first 2 months of life.~Exclusion Criteria:~* Participation in another clinical trial in the 4 weeks preceding the first trial vaccination~* Planned participation in another clinical trial during the present trial period~* Congenital or acquired immunodeficiency, immunosuppressive therapy such as long-term systemic corticosteroids therapy~* Subjects with congenital or acquired immunodeficiency in the child's surrounding~* Systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or a vaccine containing the same substances~* Chronic illness at a stage that could interfere with trial conduct or completion~* Blood or blood-derived products received since birth~* Any vaccination in the 4 weeks preceding the first trial vaccination~* Vaccination planned in the 4 weeks following the trial vaccination~* Documented history of pertussis, tetanus, diphtheria, poliomyelitis, Haemophilus influenzae type b or hepatitis B infection(s) (confirmed either clinically, serologically or microbiologically)~* Mother known as seropositive for HIV or Hepatitis C, or known carrier of Hepatitis B surface antigen~* Previous vaccination against pertussis, tetanus, diphtheria, poliomyelitis, or Haemophilus influenzae type b infection(s)~* Coagulopathy, thrombocytopenia or a bleeding disorder contraindicating IM vaccination~* History of seizures~* Febrile or acute illness on the day of inclusion.

- Gender: ALL
- Minimum Age: 50 Days
- Maximum Age: 71 Days
- Healthy Volunteers: t

Study Arms:
- Group 1: DTaP-IPV-Hep B-PRP-T (Type: EXPERIMENTAL): None
- Group 2: Tritanrix-Hep B/Hib™+OPV (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Sugammadex (Org 25969) With Neostigmine as Reversal Agents for Rocuronium or Vecuronium at Reappearance of T2 (P05960)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Is of American Society of Anesthesiologists (ASA) 1 - 4;~* Is above or equal to the age of 18;~* Scheduled for surgical procedures with a general anesthesia with the use of rocuronium or vecuronium for endotracheal intubation and maintenance of neuromuscular block;~* Scheduled for surgical procedure in supine position;~* Given written informed consent.~Exclusion Criteria:~* Participants in whom a difficult intubation because of anatomical malformations was expected;~* Is known or suspected to have neuromuscular disorders impairing neuromuscular block (NMB) and/or significant renal dysfunction;~* Is known or suspected to have a (family) history of malignant hyperthermia;~* Is known or suspected to have an allergy to narcotics, muscle relaxants or other medication used during general anesthesia;~* Is receiving medication in a dose and/or at a time point known to interfere with neuromuscular blocking agents such as antibiotics, anticonvulsants and Mg2+;~* Participants in whom the use of neostigmine and/or glycopyrrolate may be contraindicated;~* Had already participated in a sugammadex trial;~* Had participated in another clinical trial, not pre-approved by NV Organon, within 30 days of entering into P05960.~* Females who are pregnant:~* Females of childbearing potential not using any method of birth control: condom or using only hormonal contraception as birth control;~* Females who were breast-feeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rocuronium + Sugammadex (Type: EXPERIMENTAL): After the last dose of rocuronium, at reappearance of T2, a dose of 2.0 mg/kg sugammadex was administered
- Rocuronium + Neostigmine (Type: ACTIVE_COMPARATOR): After the last dose of rocuronium, at reappearance of T2, a dose of 50 ug/kg neostigmine was administered
- Vecuronium + Sugammadex (Type: EXPERIMENTAL): After the last dose of vecuronium, at reappearance of T2, a dose of 2.0 mg/kg sugammadex was administered
- Vecuronium + Neostigmine (Type: ACTIVE_COMPARATOR): After the last dose of vecuronium, at reappearance of T2, a dose of 50 ug/kg neostigmine was administered

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Aliskiren + Hydrochlorothiazide (± Amlodipine 5 mg) in Patients With Moderate Hypertension

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria for Core Study:~- Patients with mean sitting diastolic blood pressure ≥ 100 mmHg and \< 110 mmHg~Inclusion criteria for the Extension:~- msSBP ≥ 140 mm Hg and/or msDBP ≥ 90 mm Hg at Visit 5 of the core study~Exclusion Criteria for Core Study:~* Patients with mean diastolic blood pressure ≥ 110 mmHg or mean systolic blood pressure ≥ 180 mmHg~* Patients with prior stroke, hypertensive encephalopathy or heart attack~* Patients with type 1 diabetes mellitus~* Patients with type 2 diabetes mellitus with poor glucose control~Exclusion criteria for the Extension:~* Premature discontinuation in the core study or failure to comply with the core study protocol~* History of hypersensitivity to any of the study drugs or to drugs with similar chemical structures, known or suspected contraindications to diuretics as described in the SmPC (particularly amlodipine 5 mg), e.g. severe hypotension, shock - including cardiogenic shock, obstructions impairing the flow out of the left ventricle (e.g. significant aortic stenosis)~* Any patient that the investigator decides should not participate in the extension study for medical reasons~Other protocol-defined inclusion/exclusion criteria applied to the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Candesartan+HCTZ, aliskiren+HCTZ, aliskiren+HCTZ+amlodipine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treating Tobacco Dependence in Inpatient Psychiatry - 1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: Men and women over 18 years of age hospitalized on an inpatient psychiatric unit who report smoking at least 5 cigarettes per day; smoking at least 100 cigarettes in one's lifetime, residing in the San Francisco Bay Area with no plan to relocate outside of the area in the next 18 months, and access to a telephone for scheduling follow up assessments.~Exclusion Criteria: Dementia or other brain injury precluding ability to participate; non-English speaking; severe agitation, psychosis, or hostility; and medical contraindications to nicotine replacement therapy (NRT). Recruitment of acutely psychotic, manic, or hostile patients will be delayed until there is significant reduction of these symptoms. Medical contraindications are: myocardial infarction in the preceding 3 months, unstable angina pectoris, liver or kidney disease, current pregnancy or breast feeding, allergies to adhesives, or other medical conditions that the medical team deems incompatible with NRT use.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- enhanced usual care control (Type: NO_INTERVENTION): NRT during hospitalization with brief advice to stay quit once discharged
- stage-tailored intervention (Type: EXPERIMENTAL): NRT during hospitalization with brief advice to stay quit once discharged plus a computer-delivered stage-tailored smoking cessation intervention with manual and counseling plus 10-weeks of nicotine patch available post-hospitalization

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Completed study drug treatment in a parent study i.e.VX17-445-102 (NCT03525444) and VX17-445-103 (NCT03525548); or had study drug interruption(s) in a parent study but completed study visits up to the last scheduled visit of the Treatment Period in the parent study.~Exclusion Criteria:~* History of drug intolerance in a parent study that would pose an additional risk to the subject in the opinion of the investigator.~* Current participation in an investigational drug trial (other than a parent study)~Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ELX/TEZ/IVA (Type: EXPERIMENTAL): Treatment Period: Participants received ELX 200 milligram (mg) once daily (qd)/TEZ 100 mg qd/IVA 150 mg every 12 hrs (q12h) in the treatment period for 192 weeks.~Extension Period: Participants from certain countries participated in extension period and continued to receive ELX 200 mg qd /TEZ 100 mg qd/IVA 150 mg q12h in the extension period for 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and Efficacy of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject provides written informed consent.~* Intact parathyroid hormone (PTH) at least 350 pg/mL.~* Corrected calcium at least 9.0 mg/dL.~* Hemoglobin at least 9.0 g/dL.~* Adequate hemodialysis three times per week.~* Excepting chronic renal failure, subject is judged to be in stable medical condition based on medical history, physical examination, and routine laboratory tests.~Exclusion Criteria:~* History or symptomatic ventricular dysrhythmias.~* History of angina pectoris or congestive heart failure~* History of myocardial infarction, coronary angioplasty, or coronary artery bypass grafting within the past 6 months.~* History of or treatment for seizure disorder.~* Recent (3 months) parathyroidectomy.~* Serum transaminases (alanine aminotransferase, aspartate aminotransferase) greater than two times the upper limit of normal at screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Etelcalcetide (Type: EXPERIMENTAL): Participants received etelcalcetide administered by intravenous injection at the end of each hemodialysis session three times a week (TIW). The starting dose level was 5 mg; dose escalation was to proceed to 10 and 20 mg pending safety review of the prior cohort.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo administered by intravenous injection at the end of each hemodialysis session three times a week (TIW).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Evaluate the Efficacy and Safety of Two Concentrations of VBP-926 Solution for the Treatment of Chemotherapy-associated Paronychia in Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females aged 18 years or older~* Acute paronychia developing during the course of their monotherapy or combination chemotherapy~* Involvement of at least one nail with a Paronychia Severity Grading score of 1 or higher~* Eastern Cooperative Oncology Group score ≤ 2~* Life expectancy of at least 12 months as per the investigator's judgment~* Willing to provide written informed consent~* Individuals who are willing to not start any new products OTC or prescription treatments for Paronychia and discontinue any treatment the investigator feels may interfere with the evaluation of the test products~* Individuals who are already on antibiotics as prescribed by oncologist for any condition except paronychia~* Individuals who are willing to avoid using cosmetic products, creams, salves, or ointments to the treatment area(s)~Exclusion Criteria:~* Mentally incompetent or unable or not willing to give written informed consent or meet study requirements~* Without a history of a cancer diagnosis~* Without history of cancer diagnosis using chemotherapy~* Patients with paronychia requiring surgical intervention at baseline~* Patients who are already on prescribed treatment for paronychia who are not willing to discontinue this treatment and only use study drug (no washout period required)~* Neutropenia (absolute neutrophil count \< 1500 cells/µL)~* Patient Human Immunodeficiency Virus (HIV) infection~* Patients with any medical condition, including alcohol or drug abuse or mental incapacity / hypersensitive to the study drug, which in judgment of the investigator will interfere with the patient's participation in the study or evaluation of study results~* Have any medical condition that, in the opinion of the investigator, may interfere with the study results or place the subject at undue risk

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lower concentration VBP-926 (Type: ACTIVE_COMPARATOR): VBP-926 solution applied to affected area BID
- Higher concentration VBP-926 (Type: ACTIVE_COMPARATOR): VBP-926 solution applied to affected area BID
- Vehicle (Type: PLACEBO_COMPARATOR): Vehicle solution applied to affected area BID

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of a Psychotherapeutic Intervention Model in Nursing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18-64 years old;~* Nursing Diagnosis Anxiety (according to ICNP/NANDA standardized nursing language) - assessment using NOC outcome Anxiety Level (Portuguese version);~* Elementary education (completed).~Exclusion Criteria:~* Psychiatric diagnosis of dementia or psychotic spectrum disorder;~* Being in therapy provided by a psychologist (at the moment of the session 0);~* Cognitive impairment (assessment using Mini-Mental State Examination);~* Moderate or severe intellectual disability;~* Confusional state;~* Psychomotor agitation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Psychotherapeutic Intervention(s) for Anxiety (Type: EXPERIMENTAL): People diagnosed with Anxiety (according to ICNP/NANDA standardized nursing language) will be treated using Nursing Interventions Classification (NIC) psychotherapeutic intervention(s) for anxiety (plus psychopharmaceuticals).
- Treatment-as-Usual for Anxiety (Type: ACTIVE_COMPARATOR): People diagnosed with Anxiety (according to ICNP/NANDA standardized nursing language) will receive treatment as usual for anxiety (psychopharmaceuticals).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete